VC
MSLE

Vivo Capital’s Satellos Bioscience MSLE Stock Holding History

Vivo Capital’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.33M Hold
813,666
– – 0.58% 37
2026
Q1 		$4.58M Buy
+813,666
New +$7.99M 0.38% 37

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vivo Capital's MSLE Position: Q2 2026 in Review

Vivo Capital held its Satellos Bioscience (MSLE) position steady in Q2 2026 at 813,666 shares worth $6.33M. The position accounts for 0.58% of the portfolio, ranked #37.

Vivo Capital first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Vivo Capital held 813,666 shares of Satellos Bioscience worth $6.33M as of Q2 2026.
  • Vivo Capital left its Satellos Bioscience share count unchanged in Q2 2026.
  • Satellos Bioscience made up 0.58% of Vivo Capital's portfolio in Q2 2026, its #37 holding.
  • Vivo Capital first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.